Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496265 | 0.83 | F10 (0.56) | F10 | |
| SCHEMBL4961883 | 0.82 | F10 (0.70) | F10 | |
| SCHEMBL4492698 | 0.80 | F10 (0.47) | F10 | |
| SCHEMBL2516293 | 0.77 | HTRA1 (0.38) | — | |
| SCHEMBL2514355 | 0.77 | NR1H2 (0.39) | — | |
| SCHEMBL13674870 | 0.77 | F10 (0.62) | F10 | |
| SCHEMBL3696443 | 0.75 | F10 (0.51) | F10 | |
| SCHEMBL4497005 | 0.73 | F10 (0.63) | F10 | |
| SCHEMBL13675146 | 0.73 | F10 (0.45) | F10 | |
| SCHEMBL15799372 | 0.72 | BIRC2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601752-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070112001-A1 | Pyrrolidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112001-A1 | Pyrrolidine derivatives | F12, F2, F11 | F10 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.